Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | ATM | Q13315 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.52 |
| ▸ | USP5 | P45974 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16509081 | 0.90 | CYP1A1 (0.62) | ALDH1A1RAB9AHPGDKMT2AMEN1 | |
| SCHEMBL6925996 | 0.89 | TP53 (0.62) | ALDH1A1RAB9AHPGDKMT2AMEN1 | |
| SCHEMBL6929377 | 0.88 | CYP1A1 (0.68) | KMT2AMEN1ATMGAAMAPT | |
| SCHEMBL6927772 | 0.86 | CYP1A1 (0.56) | ALDH1A1RAB9AKMT2AMEN1ATM | |
| SCHEMBL6929716 | 0.86 | ALDH1A1 (0.67) | ALDH1A1KMT2AMEN1ATMGAA | |
| SCHEMBL9517500 | 0.86 | ALDH1A1 (0.68) | ALDH1A1RAB9AHPGDKMT2AMEN1 | |
| SCHEMBL11182406 | 0.83 | ALDH1A1 (0.56) | ALDH1A1RAB9AKMT2AMEN1ATM | |
| SCHEMBL6932654 | 0.83 | POLB (0.66) | ALDH1A1KMT2AMEN1ATMGAA | |
| SCHEMBL6931845 | 0.83 | THRA (0.69) | ALDH1A1KMT2AMEN1ATMGAA | |
| SCHEMBL6924351 | 0.83 | THRA (0.69) | ALDH1A1KMT2AMEN1ATMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624196-B2 | Particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, cardiovascular disorders | WARNER-LAMBERT COMPANY | 2003-09-23 | — | — | US | claimed |
| US-6541521-B1 | Particularly gelatinase A, collagenase-3, and stromelysin-1 | WARNER-LAMBERT COMPANY | 2003-04-01 | — | — | US | claimed |
| US-20020161050-A1 | Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY (US) | 2002-10-31 | — | — | US | claimed |
| CN-106905175-B | A kind of preparation method of p-aminophenyl butyric acid | 厦门市瑞思医药科技有限公司 | 2019-06-04 | — | — | CN | disclosed |
| CN-106905175-A | A kind of preparation method of p-aminophenyl butyric acid | 厦门市瑞思医药科技有限公司 | 2017-06-30 | — | — | CN | disclosed |
| US-6624196-B2 | Particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, cardiovascular disorders | WARNER-LAMBERT COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-6541521-B1 | Particularly gelatinase A, collagenase-3, and stromelysin-1 | WARNER-LAMBERT COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-20020161050-A1 | Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY (US) | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161050-A1 | Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases | MMP1, MMP8, MMP13 | ALDH1A1 1135/4885RAB9A 2177/4885HPGD 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.